Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 17 |
| Active Pipeline (Recruiting Now) | 12 (11) |
| Completed vs Stopped Early | 5 / 0 (0.0%) |
| Median Closed Actual Enrollment | 26 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Henan Cancer Hospital | Zhengzhou, Henan | 11 |
| Shandong Cancer Hospital | Jinan, Shandong | 10 |
| Sun Yat-sen University Cancer Center | Guangzhou, Guangdong | 10 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT07111546 | A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 02(BTC&HCC)] | Phase II | RECRUITING |
| NCT06783647 | A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)] | Phase II | RECRUITING |
| NCT07390383 | A Phase II Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumour[Substudy 04] | Phase II | RECRUITING |
Explore interactive annual charts and M&A subsidiary rollups in the Nanjing Leads Biolabs Co Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.